Abstract
Summary: Vasohibin-1 and Vasohibin-2 regulate angiogenesis, tumour growth and metastasis. Their molecular functions, however, were previously unknown, in large part owing to their perceived lack of homology to proteins of known structure and function. To identify their functional amino acids and domains, their molecular activity and their evolutionary history, we undertook an in-depth analysis of Vasohibin sequences. We find that Vasohibin proteins are previously undetected members of the transglutaminase-like cysteine protease superfamily, and all possess a non-canonical Cys-His-Ser catalytic triad. We further propose a calcium-dependent activation mechanism for Vasohibin proteins. These findings can now be used to design constructs for protein structure determination and to develop enzyme inhibitors as angiogenic regulators to treat metastasis and tumour growth.
Contact: luis.sanchezpulido@dpag.ox.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Tight regulation of angiogenesis contributes to normal physiology, growth and development, but when misregulated leads to, or dramatically affects, pathological conditions, such as ischaemia, wound healing and cancer (Ferrara and Kerbel, 2005). Angiogenesis is a fundamental step in transitioning tumours from benignancy to malignancy. The use of angiogenesis inhibitors in treating cancer has thus received considerable attention over the last four decades (Bergers and Benjamin, 2003).
Vasohibin-1 (VASH1) was initially identified as a vascular endothelial growth factor inducible gene that regulates endothelial cell migration (Watanabe et al., 2004; Sato, 2013; Sato, 2015). Despite lacking a classical secretion signal, human VASH1 protein is released extracellularly, assisted by a small vasohibin-binding protein which is the only known VASH1-interacting protein (Suzuki et al., 2010). Over-expression of a paralogue, Vasohibin-2 (VASH2), is associated with diverse tumours, with major roles to angiogenesis, malignant transformation, and metastasis (Kim et al., 2015; Kitahara et al., 2014; Koyanagi et al., 2013; Shibuya et al., 2006; Takahashi et al., 2012; Tu et al., 2014; Xue et al., 2013). Knockout mouse studies have revealed the contrasting roles of the two paralogues (Ito et al., 2013). VASH1 is expressed in endothelial cells in zones within which angiogenesis is arrested, whilst VASH2 is expressed in infiltrating mononuclear cells at the sprouting front in which angiogenesis is enhanced (Kimura et al., 2009). The molecular activity of neither paralogue is known, in large part due to a perceived lack of homology to proteins of known structure and function.
2 Results and discussion
2.1 Computational protein sequence analysis
We initiated our analyses by performing a JackHMMER iterative search (Finn et al., 2015) starting from the human VASH1 protein sequence, against the UniRef50 database (Wu et al., 2006). With the exception of fungi, the vasohibin family is widely distributed in eukaryotes: in animals it is represented from humans to placozoans (Trichoplax adhaerens), but is absent from nematodes (Caenorhabditis elegans) and hexapods (Drosophila melanogaster), and in plants homologues are present from green algae to Bryophytes (Physcomitrella patens) but are not in vascular plants. We identified an evolutionarily conserved central region in the vasohibin family, thereby reproducing this unusual phyletic distribution reported in Pfam (Family: vasohibin/PF14822) (Punta et al., 2012). Vasohibin homologous sequences were identified in standard databases (UniProt, GenBank and Joint Genome Institute data) and in manually assembled ESTs and FGENESH+-predicted gene models (Solovyev et al., 2006).
Next, we took advantage of HMMer3 and HMMer2 (Eddy, 1996; Finn et al., 2015) to search UniRef50 for more divergent vasohibin homologues using a hidden Markov model (HMM) generated from the central conserved region (corresponding to human VASH1, UniProt: VASH1_HUMAN, amino acids 125–247). With this profile, HMMer3 identified significant (E-value = 0.011) sequence similarities between the vasohibin HMM and a cryptophyte algae protein from Guillardia theta (UniProt: L1IQR7_GUITH, amino acids 120–227). This G. theta protein is a member of an experimentally uncharacterised family (henceforth, the ‘vasohibin-like’ family) drawn from phylogenetically heterogeneous organisms. These include Acidobacteria (Solibacter usitatus and Acidobacteriaceae bacterium), Proteobacteria (Bdellovibrio exovorus and Reyranella massiliensis), and eukaryotes (G. theta, Chaetosphaeridium globosum, Chlorokybus atmophyticus and the dinoflagellate Karlodinium veneficum; Fig. 1 and Supplementary Figure S1).
Profile-versus-sequence (HMMer2 and HMMer3) (Eddy, 1996; Finn et al., 2015) and profile-versus-profile (HHpred) (Söding et al., 2005) similarity searches using an HMM representing the central conserved portion of the vasohibin-like family produced concordant results, identifying robust statistical significance (HMMer2 E-value = 0.03 and HMMer3 E-value = 1.2 × 10−5) for the sequence similarity between vasohibin and vasohibin-like families (Supplementary Figure S2).
Unexpectedly, HHpred searches against the PDB70 profile database (Söding et al., 2005), again using the conserved central region of the vasohibin-like family, matched the transglutaminase-like cysteine protease domain of Cytophaga hutchinsonii protein (PDB-ID: 3ISR) with a highly significant E-value of 6.5 × 10−4 (Fig. 1 and Supplementary Figure S2). Moreover, in support of this first match, the next most statistically significant matches were to five further members of the transglutaminase-like cysteine protease superfamily [PDB-IDs: 3KD4, 4FGQ (LapG), 2F4M, 2BSZ (NAT1) and 4DMO (NAT3)]. Many members of this superfamily are functionally and structurally characterized enzymes classified in different protein databases, such as: Pfam (Clan Peptidase_CA CL0125, containing 60 families), SCOP (Fold: Cysteine proteinases, subdivided in 22 families) and MEROPS database of peptidases (clan CA, carefully subdivided in 36 families) (Andreeva et al., 2004; Punta et al., 2012; Rawlings et al., 2014).
Additionally, secondary structure predictions of the vasohibin and vasohibin-like families corroborated this proposed homology because they yielded high similarity with known transglutaminase-like cysteine protease superfamily structures (Fig. 1).
2.2 Active site conservation, a non-canonical catalytic triad
Proteins of the transglutaminase-like cysteine protease superfamily catalyse various reactions (such as: transglutaminases, proteases, phytochelatin synthases and arylamine N-acetyltransferases) on diverse substrates. Nevertheless, they all contain a conserved catalytic triad (usually Cys-His-Asp/Glu) (Chatterjee et al. 2012; Ginalski et al., 2004; Keillor et al., 2014; Makarova et al., 1999, 2000; Polgár and Asbóth, 1986; Vivares et al., 2005). These amino acids are conserved as Cys-His-Ser/Thr in human VASH1 and all its homologues at sites that structurally superimpose onto the transglutaminase active centre residues (Fig. 1). This modified catalytic triad (Cys-His-Ser/Thr) thus appears to be essential for the normal function of the vasohibin family.
Active sites and catalytic mechanisms of transglutaminase-like cysteine proteases have been extensively studied (Keillor et al., 2014; Polgár and Asbóth, 1986). In the classical Cys-His-Asn/Asp catalytic triad, the Cys, activated as a thiolate anion by the His residue, plays the major role in the nucleophilic attack the substrate. Both positions, His and Cys, are completely conserved across all members of the vasohibin family (VASH1 residues C169 and H204) (Fig. 1).
The third position of the catalytic triad (commonly Asn, Asp or Glu) is known to have a secondary role in catalysis by orienting the His side chain to allow the formation of a thiolate/imidazolium ion pair between Cys and His residues (Vernet et al., 1995). Such a role, we suggest, could also be performed by the hydroxyl groups of the conserved Ser or Thr amino acids (VASH1 residue S221) (Fig. 1). This non-canonical catalytic triad (Cys-His-Ser/Thr) present in the Vasohibin family, is not unique to the transglutaminase-like cysteine protease superfamily, because members of the Transglut_core family (Pfam entry: PF01841) (Punta et al., 2012), part of the transglutaminase-like cysteine protease superfamily, also contain a Cys-His-Thr non-canonical catalytic triad (e.g. A0LIH5_SYNFM from Syntrophobacter fumaroxidans). Another example of a non-canonical catalytic triad is the Cys-His-(O=C)Trp triad in mSpeB (PDB: 1dki) (Kagawa et al., 2000), where the role of orienting the His residue is taken by the backbone carbonyl group of a Trp amino acid. Despite containing this unconventional catalytic triad, mSpeB is an unusually active protease (Honda-Ogawa et al., 2013).
2.3 Activators, inhibitors and regulators in the Transglutaminase-like cysteine protease superfamily
Owing to the higher concentrations of calcium in the extracellular space, diverse secreted proteins possess calcium-dependent activation mechanisms that avoid intracellular activation. Calcium dependent activation is a recurring theme across the transglutaminase-like cysteine protease superfamily (Boyd et al., 2012; Chatterjee et al., 2012; Jang et al., 2014). Calcium-binding sites show a wide range of geometries involving three or four-COOH groups (particularly aspartic and glutamic acids) plus two neutral oxygen donors (usually backbone atoms) (Wang et al., 2009). A calcium-dependent activation mechanism in vasohibin homologues is suggested by the alignment of a conserved amino acid (VASH1-E171) with a known calcium binding residue in LapG protease (LapG-D139) (Fig. 1) (Chatterjee et al., 2012). Experimental evidence will be necessary to confirm these Vasohibin family predicted calcium-binding sites.
Angiogenesis is not a new cellular process for members of the transglutaminase-like cysteine protease superfamily. Tissue transglutaminase (also known as transglutaminase 2), for example, and also different members of the cysteine cathepsin family of peptidases, have been frequently implicated in various aspects of vascular morphogenesis (Turk et al., 2012; Wang et al., 2013). The identification of the Vasohibin family as members of the transglutaminase-like cysteine protease superfamily may further clarify the known relationship between reactive oxygen or nitrogen species (ROS and RNS) and angiogenesis (Huang and Zheng, 2006; Ushio-Fukai, 2007; Ushio-Fukai and Urao, 2009). ROS and RNS are known to inactivate different members of the transglutaminase-like cysteine protease superfamily, such as papain (Xian et al., 2000), arylamine N-acetyltransferase (NAT1) (Dupret et al., 2005) and transglutaminases (Bernassola et al., 1999; Nurminskaya and Belkin, 2012). We thus suggest that the putative catalytic cysteine residues in VASH1 and VASH2 could be substrates of ROS and RNS activity.
Owing to the enzymatic diversity of its transglutaminase-like homologues, our computational analysis is unable to predict the catalytic reaction or substrate of vasohibins. Nevertheless, the discovery of vasohibins as enzyme homologues should now motivate the determination of their protein structures and the development of active site inhibitors that differentiate VASH1 from VASH2. Such inhibitors would be anticipated to modify angiogenesis and thus to be useful for inhibiting metastasis and tumour growth. We note that different inhibitors have already been described for several members of the transglutaminase-like cysteine protease superfamily (Badarau et al., 2013; Chakka et al., 2015; Keillor et al., 2015; Kerr et al., 2009; Kukongviriyapan et al., 2006; Pandey and Dixit, 2012; Sim et al., 2014; Turk et al., 1997; Zhou et al., 2013).
3 Conclusion
Given the strong statistical significance of sequence and profile comparisons, and the concordance of secondary structure predictions and conserved active site residues, we have shown that vasohibin proteins are new members of the transglutaminase-like cysteine protease superfamily, and possess a non-canonical Cys-His-Ser/Thr catalytic triad. This insight should immediately help guide experiments to clarify the molecular mechanisms by which VASH1 and VASH2 control angiogenesis.
Funding
This work was supported by Medical Research Council UK.
Conflict of Interest: none declared.
Supplementary Material
References
- Andreeva A. et al. (2004) SCOP database in 2004: refinements integrate structure and sequence family data. Nucleic Acids Res., 32, D226–D229. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Badarau E. et al. (2013) Recent advances in the development of tissue transglutaminase (TG2) inhibitors. Amino Acids, 44, 119–127. [DOI] [PubMed] [Google Scholar]
- Bergers G., Benjamin L.E. (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 3, 401–410. [DOI] [PubMed] [Google Scholar]
- Bernassola F. et al. (1999) Regulation of transglutaminases by nitric oxide. Ann. N. Y. Acad. Sci., 887, 83–91. [DOI] [PubMed] [Google Scholar]
- Boyd C.D. et al. (2012) LapG, required for modulating biofilm formation by Pseudomonas fluorescens Pf0-1, is a calcium-dependent protease. J. Bacteriol., 194, 4406–4414. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chakka S.K. et al. (2015) Identification of novel class of falcipain-2 inhibitors as potential antimalarial agents. Bioorg. Med. Chem., 23, 2221–2240. [DOI] [PubMed] [Google Scholar]
- Chatterjee D. et al. (2012) Structural characterization of a conserved, calcium-dependent periplasmic protease from Legionella pneumophila. J. Bacteriol., 194, 4415–4425. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dupret J.M. et al. (2005) Inactivation of human arylamine N-acetyltransferase 1 by hydrogen peroxide and peroxynitrite. Methods Enzymol., 400, 215–229. [DOI] [PubMed] [Google Scholar]
- Eddy S.R. (1996) Hidden Markov models. Curr. Opin. Struct. Biol., 6, 361–365. [DOI] [PubMed] [Google Scholar]
- Ferrara N., Kerbel R.S. (2005) Angiogenesis as a therapeutic target. Nature, 438, 967–974. [DOI] [PubMed] [Google Scholar]
- Finn R.D. et al. (2015) HMMER web server: 2015 update. Nucleic Acids Res., 43, W30–W38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ginalski K. et al. (2004) BTLCP proteins: a novel family of bacterial transglutaminase-like cysteine proteinases. Trends Biochem. Sci., 29, 392–395. [DOI] [PubMed] [Google Scholar]
- Holm L., Sander C. (1995) Dali: a network tool for protein structure comparison. Trends Biochem. Sci., 20, 478–480. [DOI] [PubMed] [Google Scholar]
- Holton S.J. et al. (2005) Structure of Mesorhizobium loti arylamine N-acetyltransferase 1. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun., 61, 14–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Honda-Ogawa M. et al. (2013) Cysteine proteinase from Streptococcus pyogenes enables evasion of innate immunity via degradation of complement factors. J. Biol. Chem., 288, 15854–15864. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Huang S.S., Zheng R.L. (2006) Biphasic regulation of angiogenesis by reactive oxygen species. Pharmazie, 61, 223–229. [PubMed] [Google Scholar]
- Ito S. et al. (2013) Enhanced cancer metastasis in mice deficient in vasohibin-1 gene. PLoS One, 8, e73931. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jang T.H. et al. (2014) Crystal structure of transglutaminase 2 with GTP complex and amino acid sequence evidence of evolution of GTP binding site. PLoS One, 9, e107005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones D.T. (1999) Protein secondary structure prediction based on position-specific scoring matrices. J. Mol. Biol., 292, 195–202. [DOI] [PubMed] [Google Scholar]
- Kagawa T.F. et al. (2000) Crystal structure of the zymogen form of the group A Streptococcus virulence factor SpeB: an integrin-binding cysteine protease. Proc. Natl. Acad. Sci. USA, 97, 2235–2240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Keillor J.W. et al. (2014) Acyl transfer mechanisms of tissue transglutaminase. Bioorg. Chem., 57, 186–197. [DOI] [PubMed] [Google Scholar]
- Keillor J.W. et al. (2015) Inhibitors of tissue transglutaminase. Trends Pharmacol. Sci., 36, 32–40. [DOI] [PubMed] [Google Scholar]
- Kerr I.D. et al. (2009) Vinyl Sulfones as Antiparasitic Agents and a Structural Basis for Drug Design. J. Biol. Chem., 284, 25697–25703. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kim J.C. et al. (2015) Expression of vasohibin-2 in pancreatic ductal adenocarcinoma promotes tumor progression and is associated with a poor clinical outcome. Hepatogastroenterology, 62, 251–256.25916042 [Google Scholar]
- Kimura H. et al. (2009) Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood, 113, 4810–4818. [DOI] [PubMed] [Google Scholar]
- Kitahara S. et al. (2014) Vasohibin-2 modulates tumor onset in the gastrointestinal tract by normalizing tumor angiogenesis. Mol. Cancer, 13, 99. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Koyanagi T. et al. (2013) Downregulation of vasohibin-2, a novel angiogenesis regulator, suppresses tumor growth by inhibiting angiogenesis in endometrial cancer cells. Oncol. Lett., 5, 1058–1062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kubiak X. et al. (2013) Structural and biochemical characterization of an active arylamine N-acetyltransferase possessing a non-canonical Cys-His-Glu catalytic triad. J. Biol. Chem., 288, 22493–22505. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kukongviriyapan V. et al. (2006) Inhibitory effects of polyphenolic compounds on human arylamine N-acetyltransferase 1 and 2. Xenobiotica, 36, 15–28. [DOI] [PubMed] [Google Scholar]
- Makarova K.S. et al. (1999) A superfamily of archaeal, bacterial, and eukaryotic proteins homologous to animal transglutaminases. Protein Sci., 8, 1714–1719. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Makarova K.S. et al. (2000) A novel superfamily of predicted cysteine proteases from eukaryotes, viruses and Chlamydia pneumoniae. Trends Biochem. Sci., 25, 50–52. [DOI] [PubMed] [Google Scholar]
- Notredame C. et al. (2000) T-Coffee: a novel method for fast and accurate multiple sequence alignment. J. Mol. Biol., 302, 205–217. [DOI] [PubMed] [Google Scholar]
- Nurminskaya M.V., Belkin A.M. (2012) Cellular functions of tissue transglutaminase. Int. Rev. Cell Mol. Biol., 294, 1–97. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pandey K.C., Dixit R. (2012) Structure-function of falcipains: malarial cysteine proteases. J. Trop. Med., 2012, 345195. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Polgár L., Asbóth B. (1986) The basic difference in catalyses by serine and cysteine proteinases resides in charge stabilization in the transition state. J. Theor. Biol., 121, 323–326. [DOI] [PubMed] [Google Scholar]
- Punta M. et al. (2012) The Pfam protein families database. Nucleic Acids Res., 40, 290–301. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rawlings N.D. et al. (2014) MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res., 42, D503–D509. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sali A., Blundell T.L. (1993) Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol., 234, 779–815. [DOI] [PubMed] [Google Scholar]
- Sato Y. (2013) The vasohibin family: a novel family for angiogenesis regulation. J. Biochem., 153, 5–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sato Y. (2015) Novel Link between Inhibition of Angiogenesis and Tolerance to Vascular Stress. J. Atheroscler. Thromb., 22, 327–334. [DOI] [PubMed] [Google Scholar]
- Söding J. et al. (2005) The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res., 33, W244–W248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shibuya T. et al. (2006) Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin. Arterioscler. Thromb. Vasc. Biol., 26, 1051–1057. [DOI] [PubMed] [Google Scholar]
- Sim E. et al. (2014) Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br. J. Pharmacol., 171, 2705–2725. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Solovyev V. et al. (2006) Automatic annotation of eukaryotic genes, pseudogenes and promoters. Genome Biol., 7, 1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sonnhammer E.L., Hollich V. (2005) Scoredist: a simple and robust protein sequence distance estimator. BMC Bioinformatics, 6, 108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Suzuki Y. et al. (2010) Isolation of a small vasohibin-binding protein (SVBP) and its role in vasohibin secretion. J. Cell Sci., 123, 3094–3101. [DOI] [PubMed] [Google Scholar]
- Takahashi Y. et al. (2012) Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. Mol. Cancer Res., 10, 1135–1146. [DOI] [PubMed] [Google Scholar]
- Tu M. et al. (2014) Vasohibin-2 promotes proliferation in human breast cancer cells via upregulation of fibroblast growth factor-2 and growth/differentiation factor-15 expression. Mol. Med. Rep., 10, 663–669. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Turk B. et al. (1997) Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol. Chem., 378, 141–150. [PubMed] [Google Scholar]
- Turk V. et al. (2012) Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta, 1824, 68–88. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ushio-Fukai M. (2007) VEGF signaling through NADPH oxidase-derived ROS. Antioxid. Redox Signal., 9, 731–739. [DOI] [PubMed] [Google Scholar]
- Ushio-Fukai M., Urao N. (2009) Novel role of NADPH oxidase in angiogenesis and stem/progenitor cell function. Antioxid. Redox Signal., 11, 2517–2533. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vernet T. et al. (1995) Structural and functional roles of asparagine 175 in the cysteine protease papain. J. Biol. Chem., 270, 16645–16652. [DOI] [PubMed] [Google Scholar]
- Vivares D. et al. (2005) A papain-like enzyme at work: native and acyl-enzyme intermediate structures in phytochelatin synthesis. Proc. Natl. Acad. Sci. USA, 102, 18848–18853. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang X. et al. (2009) Towards predicting Ca2+-binding sites with different coordination numbers in proteins with atomic resolution. Proteins, 75, 787–798. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang Z. et al. (2013) A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis. Cell Death Dis., 4, e808. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Watanabe K. et al. (2004) Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J. Clin. Invest., 114, 898–907. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wu C.H. et al. (2006) The Universal Protein Resource (UniProt): an expanding universe of protein information. Nucleic Acids Res., 34, D187–D191. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Xian M. et al. (2000) Inhibition of papain by S-nitrosothiols. Formation of mixed disulfides. J. Biol. Chem., 275, 20467–20473. [DOI] [PubMed] [Google Scholar]
- Xue X. et al. (2013) Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene, 32, 1724–1734. [DOI] [PubMed] [Google Scholar]
- Zhou X. et al. (2013) Arylamine N-acetyltransferases: a structural perspective. Br. J. Pharmacol., 169, 748–760. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.